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Abstract: Bone substitute materials have witnessed tremendous development over the past 
decades and autogenous bone may still be considered the gold standard for many clinicians 
and clinical approaches in order to rebuild and restore bone defects. However, a plethora of 
novel xenogenic and synthetic bone substitute materials have been introduced in recent 
years in the field of bone regeneration. As the development of bone is actually a 
calcification process within a collagen fiber arrangement, the use of scaffolds in the 
formation of fibers may offer some advantages, along with additional handling 
characteristics. This review focuses on material characteristics and degradation behavior of 
electrospun biodegradable polyester scaffolds. Furthermore, we concentrated on the 
preclinical in vivo performance with regard to bone regeneration in preclinical studies. The 
major findings are as follows: Scaffold composition and architecture determine its 
biological behavior and degradation characteristics; The incorporation of inorganic 
substances and/or organic substances within composite scaffolds enhances new bone 
formation; L-poly(lactic acid) and poly(lactic-co-glycolic acid) composite scaffolds, 
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especially when combined with basic substances like hydroxyapatite, tricalcium phosphate 
or demineralized bone powder, seem not to induce inflammatory tissue reactions in vivo. 
Keywords: 3D scaffold; biodegradable polymer; bone; calcium phosphate; calvarial 
defect; electrospinning; experimental animal models; nanocomposite 
 
1. Introduction 
The reconstruction of bone that has been lost due to pathologic changes or injury is a major interest 
in preclinical and clinical research and has led to the development of a plethora of materials that should 
help to efficiently regenerate or at least repair bone defects [1–3]. Autografts still remain the gold 
standard material, i.e., the harvesting of bone from the patient but from a non-injured site, but the need 
for a second intervention procedure, donor site morbidity, and an often limited supply of bone are 
associated with this intervention and limit this approach [1]. Alternatives are therefore allografts, i.e., 
bone material from an individual of the same species, but again this may entail other problems such as 
rejection or disease transmission [4]. 
As an alternative to these tissue-based strategies, synthetic bone substitutes that act as scaffolds can 
be used and implanted. Whereas metals are the material of choice for load-bearing indications, due to 
their good mechanical properties, ceramics exhibit a higher biocompatibility as their chemical 
composition resembles the mineral phase of bone tissue. However, both materials are generally poorly 
degradable and, thus, not used for smaller defects, and they cannot be used as solid body implant materials. 
Biodegradable polymers, such as poly(lactic acid) (PLA) and the co-polymer  
poly(lactic-co-glycolic acid) (PLGA) have been widely investigated and applied to fabricate porous 
scaffolds in order to restore damaged tissue [5,6]. A variety of biomedical materials have been 
developed to fulfill the mechanical and biological demands that the various tissues require. Amongst 
these, a flexible, moldable, electrospun cotton wool-like nanocomposite has been proposed [7–9]; it 
incorporates amorphous calcium phosphate nanoparticles into a biodegradable synthetic PLGA. This 
material is prepared through an electrospinning process, which gives it the typical cotton wool-like 
appearance. This characteristic of the material allows easy proportioning, handling, and adaption to 
any bone defect. Preclinical studies have shown high bioactivity of this material as soon as four weeks 
after implantation, with the formation of new bone and increased cell density. Resorption of the  
graft material as early as four weeks after surgical placement was also reported [9]. The authors  
highlighted the need for further investigations in animal models to evaluate the long-term  
stability and clinical outcomes of this material. Since then, many more study groups have assessed 
similar scaffolds based on PLA and PLGA as a carrier material in an electrospun form that can  
be used as a carrier for many inorganic materials in an appropriate size and form, mostly  
incorporated as nanoparticles. 
As PLA and PLGA degrade mainly by hydrolysis, there is still some concern regarding the host 
tissue response to their degradation products. These metabolites have been shown to exhibit  
a toxic influence on cell culture systems in vitro for high concentrations [10]. Despite the fact that 
there is a large number of materials on the market, the present review aims to summarize, in the first 
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part, the most important aspects of the applied biodegradable materials and, in the second part, to 
screen the literature with regard to the biocompatibility of these materials when implanted in animals, 
given the still remarkably controversial background on the degradation of PLA- and PLGA-based 
electrospun materials. 
2. Material Characteristics and Degradation Behavior 
Nowadays, medical implants are used to help prolong the lifespan of humans and facilitate  
the life of elder people. Biomaterial science is characterized by the search for improved 
biocompatibility, enhanced cell-material interaction, tailored degradation, integrative biomaterials 
design, and other specific properties [11] of polymers, metals, and ceramics. These three materials 
represent the classes that are used to create biomaterials either as a pure material or, most of the time,  
as a composite product. 
Polymers represent a mere organic matrix and the physical and chemical properties vary 
tremendously, depending on the application area, like wound dressing, orthopedics, cardiovascular 
interventions, or drug delivery. This material class can be subdivided into two categories that are 
important for medical devices, biodegradable vs. non-biodegradable polymers. One of the main 
advantages of biodegradable polymers is the prevention of implant removal and the circumvention  
of a persistent foreign body; plus, these polymers can be engineered so that they degrade at a certain 
rate in order to transfer load to a healing bone [12,13]. Biodegradable polymers are further  
divided into naturally derived materials, including proteins or polysaccharides, and synthetically 
prepared materials, mainly aliphatic polyesters. Focusing on the latter polymer, some of the most 
often-used materials are saturated poly-α-hydroxy esters, including poly(glycolic acid) (PGA), PLA, 
and the co-polymer thereof PLGA [6]. The clearage of the degradation products by natural pathways 
out of the body and the long history of use might be the reasons that they are the most  
commonly used and the most widely investigated degradable polymers. PGA is a highly crystalline 
aliphatic polyester with a high melting point and low solubility in organic solvents. It is more 
hydrophilic than PLA and degrades faster. PLA appears mainly as L-PLA (PLLA), D-PLA (PDLA), 
and as racemic mixture D,L-PLA (PDLLA). The optically inactive form, PDLLA, is always 
amorphous, while the two others are semicrystalline [14]. This difference also determines the 
application areas for the various PLA forms. PDLLA is often considered as a drug delivery vehicle, 
due to its monophasic form, while PLLA is preferred for applications where a high mechanical 
strength is necessary. It is possible to adapt the degradation rate for a specific application by the 
combination of PLA and PGA. It has to be noted that a 50/50 copolymer ratio of lactic and glycolic 
acid has the fastest degradation rate, yet there is no linear relationship for the degradation kinetics of 
the two components [15]. In general, the physical and mechanical properties are adjustable and depend 
on the molecular weight, the polydispersity, and the co-polymer ratio. However, the degradation rates 
depend not only on the molecular weight but also on the environmental conditions, the device size and 
form, and on any additives in the polymer. 
Most of the polymers, although partially hydrophobic, have a hydrophilic nature, which is  
dominant enough that the rate of water penetration into the material excels the rate of degradation. 
Therefore, they undergo mostly a bulk erosion process. However, the characteristic size of a  
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device can also lead to a surface erosion process [16]. This fact has to be taken into account  
when designing a device for a specific application. Although there are different mechanisms of  
erosion [14], the main cause for the aliphatic polyesters described here is the hydrolytic degradation  
by de-esterification of the polymer backbones. As the degradation proceeds, the carboxylic end  
groups auto-catalyze the degradation process via the low pH and the cleavage of the backbone is 
enhanced [17]. 
Of particular interest for the design of a medical implant, next to the degradation rate  
(tailored by additives or the polymer chain length), is the size of the polymer matrix (morphology) 
itself [18] and, of course, the polymer composition [19]. The acidic degradation products of PLA, 
PGA, or PLGA can, on the one hand, induce an early failure of the implant, and can, on the  
other hand, start an adverse tissue reaction in the body [20], but do not necessarily have to [21]. 
Athanasiou et al., reported different results (with and without inflammation) using PLLA  
at different sites in rat models [22]. Often other factors, such as leachable impurities from the 
synthesis, can also trigger inflammation [23]. Polymer additives are often of an inorganic nature,  
namely a ceramic such as tricalcium phosphate (TCP), hydroxyapatite (HA), or bioactive  
glass (BG), and are either used to dose the degradation [24] and/or to counteract the effects  
of the degraded by-products due to their alkaline nature. Additionally, polymers can benefit from  
these additives as they render the composite material so-called bioactive, which is the ability  
of the composite material to bond to bone tissue [25]. This term is generally used within 
biomineralization studies and describes the ability of a material to form calcium phosphate  
depositions when immersed in simulated body fluids. 
Several techniques are applied to combine the organic and inorganic materials in order to better  
suit the demands of a specific application [6]. Today, various shapes of foams, meshes, films,  
fibers, or microspheres are manufactured with the ulterior motive to be dedicated to a specific  
utilization. In order to take advantage of a high surface to volume ratio and, thus, of a possible  
higher reactivity potential, fibers offer a tremendous advantage over films or rigid blocks. 
Additionally, the manufactured composite is highly flexible and shapeable. This advantage can  
be of importance for bone tissue engineering as the operation site is sometimes difficult to reach. The 
method of choice today to produce ultrathin fibers is electrospinning [26]. This tool allows the  
preparation of open-structured and highly flexible scaffolds for applications in filtration, wound 
dressing, tissue engineering, or reinforcement. Furthermore, a fibrous architecture can positively  
affect cell ingrowth [26]. Electrospinning of various polymer systems and composites into mats, 
meshes, and scaffolds for tissue engineering and drug delivery has been described in detail [27,28]. 
Further, it has been shown that incorporating inorganic particles, preferentially in a nanoparticulate 
form to achieve a homogenous distribution (Figure 1), with biodegradable polymers enables  
the production of highly flexible and reactive nanocomposites [7,29] that can be advantageous  
for tissue engineering applications. Several in vitro studies have shown that electrospun  
composite materials performed well, but only a few in vivo studies have been conducted so far. 
Whether the acidic degradation products of the biodegradable PLA or PLGA can trigger inflammatory 
reactions and whether electrospun materials can perform well are still on-going research topics in 
biomaterials science. 
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Figure 1. (a) Photographic image of a flexible electrospun poly(lactic-co-glycolic acid)/ 
tricalcium phosphate (PLGA/TCP) (60/40) composite material. (b) Electron microscopy 
image of an electrospun PLGA/TCP (60/40) composite material showing an open and 
porous structure. 
3. Biocompatibility in Preclinical Studies 
3.1. Aim of the Review on Biocompatibility 
This review was performed in order to specifically study the biocompatibility of electrospun PLA 
and PLGA scaffolds for bone regeneration when applied in vivo, focusing on preclinical studies. In 
addition, the potential effects of scaffold-related factors (e.g., molecular weight, co-polymer 
composition, and fiber diameter of PLA and PLGA), host-related factors (e.g., animal model or defect 
type), and possible tissue reactions on the degradation process of PLA and PLGA were also evaluated 
if applicable. 
3.2. Search Strategy 
An electronic search of the published literature was conducted on the following databases: Embase, 
Medline, PubMed Premedline, Biosis Previews, and Scopus. Papers were included if published by 
April 2015. 
The following key words, separately or in combination, were used: (((glycolic[tiab] OR 
polyglycolic[tiab]) AND (lactic[tiab] OR polylactic[tiab])) OR (lactic acid[tiab] AND poly[tiab]) OR 
polylactate[tiab]) AND (electrospun[tiab] OR electrospinning[tiab] OR fibrous[tiab] OR 
nanofibrous[tiab] OR fiber[tiab] OR fibers[tiab] nanofiber[tiab] OR nanofibers[tiab]) AND  
(bone[All Fields] OR osseous[All Fields]) AND (mouse[All Fields] OR mice[All Fields] OR  
rat[All Fields]OR rats[All Fields] OR hamster[All Fields] OR hamsters[All Fields] OR guinea  
pig[All Fields] OR guinea pigs[All Fields] OR monkey[All Fields] OR monkeys[All Fields] OR 
rabbit[All Fields]OR rabbits[All Fields] OR human[All Fields] OR humans[All Fields] OR  
animal[All Fields] OR animals[All Fields]) AND (publisher[sb] OR inprocess[sb]). 
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3.3. Review Process 
Two independent reviewers (Claudia Holderegger and Patrick R. Schmidlin) performed the 
assessment of eligibility and data extraction. Any disagreement was resolved by discussion and, if 
necessary, by communication with a third reviewer (Dirk Mohn). 
Initial screening of titles was followed by an abstract screening using the following inclusion 
criteria: publication in German or English language; animal clinical trials; electrospun PLA or PLGA 
scaffolds when explicitly used for guided bone regeneration in critical or non-critical bone defects; 
assessment of the amount of new regenerated bone and the registration of possible tissue reactions. 
Studies were excluded for the following reasons: human studies, case reports, reviews, bone 
regeneration with non electrospun PLA or PLGA, or electrospun PLA or PLGA scaffolds mixed or 
coated with organic substances without pure PLA or PLGA control groups. 
Subsequently, full text of all possibly relevant papers were checked for the fabrication and the 
characterization of the PLA and PLGA scaffolds, the in vivo experimental model, the defect type, the 
methods of evaluating bone regeneration, the methods of evaluating inflammation reactions and 
histological assessments, and the obtained results. Duplicate articles were identified and removed. 
3.4. Results 
During the initial search, 839 references were identified. After the screening of these titles, abstracts 
and full texts, 10 papers could be found [9,30–38], which finally formed the basis of this systematic review. 
3.4.1. Description of Materials 
Within the identified literature, seven studies examined PLLA [30–32,34,35,37,38] whereas only 
three studies used PLGA [9,33,36]. 
Two studies reported a ratio of 85:15 regarding their components of PLGA, which relates to a  
co-polymer composed of 85% lactic and 15% glycolic acid [9,36]. One study did not declare the exact 
composition of the used PGLA [33]. All lactic acid polymers consisted of L-lactic acid,  
PLLA [30–32,34,35,37,38]. 
One factor influencing the degradation process of the PLLA/PLGA-containing scaffolds is the 
molecular weight, which is usually given in Da or g/mol. By increasing the molecular weight of 
conventional PLGA from 10–20 kDa to 100 kDa, degradation rates can change from several weeks to 
several months [39,40]. One study used PLGA of 80,000 Da [36], whereas another study used PLGA 
with different molecular weights (380,300 g/mol to 181,900 g/mol) [9]. One investigation used PLLA of 
300,000 Da [35]. All other studies did not report about the molecular weight of the applied materials. 
Some manufacturers characterized their product declaring its viscosity, which is influenced by 
various factors such as temperature, polymer concentration, polymer chain length, and applied solvent, 
yet it is correlated to the molecular weight. The viscosity of PLLA solutions significantly varied in this 
review from 0.9 to 8.2 dL/g [31,32,37,38]. According to the manufacturer’s datasheet the 0.9 dL/g 
correlates to about 150,000 Da. 
In addition, as the scaffold architecture affects PLLA/PLGA degradation and the biological behavior 
depends also on the accessibility of water, blood vessels, and cells, the fiber diameter plays an important 
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role. The studies in this review reported about fiber diameters of PLGA ranging from 300 nm [33,36] 
to 10 µm [9], whereas PLLA fibers varied from 300 nm [30,31,34,37] to 7 µm [31,32,38]. 
With regard to tissue engineering, the porosity of scaffolds strongly influences the diffusion area 
and, thus, the flow rate of nutrients and metabolic products throughout the scaffolds [41]. As a 
consequence of this, porosity facilitates the process of local vascularization that is essential for tissue 
growth and, vice versa, porosity can affect the mechanical strength of scaffolds. The scaffold 
architectures of the studies in this review are described in Table 1. None of the studies declared the 
pore diameter of the electrospun fibers. However, the orientation of fibers in the scaffold profoundly 
affects cell migration as well. Lee et al. [38] showed that human mesenchymal stem cells migrated 
10.46-fold faster along the parallel direction than along the perpendicular direction on PLLA 
nanofibers. Electrospun scaffold parameters, such as the solution concentration, the solvent properties, 
the voltage, the solution flow rate, and the distance between needle type and collector, influence fiber 
characteristics and orientation and, as a consequence of this, the scaffold architecture [42]. 
To improve mechanical and biological properties of PLLA/PLGA scaffolds, inorganic additives are 
often used. They can either be used as reinforcing material of the scaffold or as coating material to 
improve bone tissue response towards PLLA/PLGA scaffolds. In this review, PLGA scaffolds were 
used with willmite [33], HA [36], or TCP [9]. As an organic adjunction, one PLGA study used 
simvastatin (SIM) [36]. 
PLLA scaffolds were combined with HA [32,34,35], TCP [34], or BG [34]. Organic materials like 
dopamine (DA) [38], demineralized bone powders (DBP) [37], and bone morphogenic protein-2 
(BMP-2) [30] were additionally used to improve cell interaction on the surface of PLLA biomaterials. 
In this regard it is important to know the relevant information on the composition and architecture 
of scaffolds because this highly influences the biological behavior. Unfortunately, important 
information about polymer construction or molecular weight was often missing, complicating the 
overall scientific comparison of the materials in more detail. 
3.4.2. Description of Experimental Methods 
All pre-clinical in vivo experiments in this review used a calvarial defect model (Table 2). All of 
them were performed on rats [30,32–37], rabbits [9,31], or mice [38]. Six of them used a calvarial 
critical size model [30,33–35,37,38], which means that bone defects were too large-dimensioned for 
spontaneous bone healing. Non-critical size defect models were chosen in the remaining four  
studies [9,31,32,36]. The time of evaluation or sacrificing the animals was four [9,30–32,36], six [35],  
eight [30,33,34,36–38], 10 [35], or 12 weeks [30], respectively. All defects were sutured and resulted 
in closed defect healing. Adegani et al. [33] were the only authors who did not declare the procedure 
of wound closure in their study explicitly. One experiment [37] covered the implanted defects with a 
polyvinyl membrane to minimize the effect of self-renewal capability by the pericranium. Evaluation 
methods of newly formed bone and the biological behavior of the PLLA/PLGA scaffolds comprised 
multi-slice spiral-computed tomography [33,34], micro-computed tomography (micro-CT) [9,35–38] 
digital mammography [34], radiographic analysis [9,35], scanning electron microscopy [38], 
hematology, or biochemistry [35]. All studies performed a histological evaluation [9,30–38]. 
Table 1. Description of L-poly(lactic acid)/poly(lactic-co-glycolic acid) (PLLA/PLGA) materials and scaffold characterization. 
Author Scaffold Components Scaffold Architecture Fiber Diameter 
Adegani et al. [33] 
PLGA 15% (wt/wt) solution dissolved in DMF/THF  
coating with willmite nanoparticles 
porous structure 
300 ± 500 nm; willmite coating  
did not affect fiber diameter 
Dinarvand et al. [34] 
PLLA dissolved in chloroform with a 4% (w/v) concentration  
coating with HA, BG, TCP; HA + BG 
nanofibrous structure with homogeneous distribution of  
bioceramics along the surface of PLLA 
822 ± 97 nm 
Jaiswal et al. [35] 
PLLA with molecular weight 300,000 Da blend with G (3:1)  
composited with HA 
no information no information 
Jiang et al. [36] 
PLGA (85:15) 10% with molecular weight of 80,000 Da  
dissolved in a mixture of chloroform + DMF (1:1) mixed  
with HA (20:1) mixed with HA + SIM (20:1:1) 
scaffolds with smooth and nanofibrous morphology 
PLGA: 550 ± 50 nm  
PLGA + HA: 240 ± 30 nm  
PLGA + HA + SIM: 270 ± 30 nm 
Lee et al. [38] 
PLLA (5.7–8.2 dL/g viscosity; Resomer L 214 S) dissolved  
in HFIP (2 wt % for random, 2.5 wt % for aligned fibers)  
coating with polydopamine 
scaffolds with random and aligned fiber orientation 1 µm in both structures 
Ko et al. [37] 
PLLA (3.3–4.3 dL/g viscosity; Resomer L 210 S) dissolved  
in trifluorethanol mixed with DBP (1.0:0.2) 
nanofibrous scaffold with randomly oriented fibers with  
a homogeneous distribution 
300–700 nm 
Schneider et al. [9] 
PLGA (Resomer) (85:15) with a molecular weight of  
380,300 g/mol and 181,900 g/mol blend with TCP  
nanoparticles (40 wt %) 
fibers exhibiting a porous structure, TCP-containing  
fibers revealed an increased roughness 
5–10 µm 
Schofer et al. [30] 
PLLA (Resomer) 4% (w/w) dissolved in DCM incorporation  
of BMP-2 
three-dimensional non-woven network of nanofibers,  
fibers showed a porous structure 
775 ± 294 nm 
Shim et al. [31] 
PLLA (intrinsic viscosity 0.63 dL/g, molecular weight:  
250,000 g/mol); 8% PLLA dissolved in DCM/HFIP or in  
DCM/DMF or in DCM/acetone with volume ratios (90:10)  
3% PLLA in DCM/HFIP (90:10) 
PLLA mixture below 2% w/v resulted in beaded fibers, for  
concentrations > 4%, the fibers fused at the contact points 
400 nm–7 µm 
Yanagida et al. [32] 
PLLA (Lactel: intrinsic viscosity: 0.9–1.2 dL/g) dissolved  
in DMC at 15 wt % mixed or coated, or mixed and coated  
with HA nanocrystals 
PLLA/HA nanocomposite fibers, where HA nanocrystals  
were mixed into the PLLA matrix as well as coated onto the  
PLLA surface had submicron-sized dimples on their surfaces 
PLLA fibers: 6.1 ± 1.9 µm  
PLLA/HA mixed: 7.6 ± 1.9 µm 
BG: bioactive glass; BMP-2: bone morphogenetic protein 2; DBP: demineralized bone powder; DMF: dimethylformamide; G: gelatin; HA: hydroxyapatite; HFIP: hexafluoroisopropanol; DCM: dichloromethane; 
SIM: simvastatin; TCP: tricalcium phosphate; THF: tetrahydrofurane. 
Materials 2015, 8 9 
 
 
Table 2. Description of in vivo experiments with PLLA/PLGA scaffolds. 
Author Animal Model 
Defect Size (Diameter)  
and Wound Treatment 
Time of  
Evaluation 
Methods of Evaluation Area of Regenerated Bone 
Histological  
Results 
Adegani et al. [33] rats 
8 mm calvarial critical size  
defects, precise treatment of  
the wound is not described 
8 weeks 
MSCT histology evaluation  
by two independent radiologists 
PLGA + willmite: 70% PLGA: 35%  
Empty: 5% 
No sign of  
inflammation 
Dinarvand et al. [34] rats 
8 mm calvarial critical size  
defects, wound was closed  
with sutures. 
8 weeks 
MSCT Digital mammo-graphy  
histology evaluation by two  
independent radiologists 
PLLA-HA-BG: 63% PLLA-TCP: 44%  
PLLA-HA: 23% PLLA-BG: 20%  
PLLA: 13% Empty: 12% 
No sign of  
inflammation 
Jaiswal et al. [35] rats 
5 mm calvarial critical size  
defects, pericranium and  
skin was closed in layers 
6 and  
10 weeks 
Micro-CT digital X-ray,  
hematology and serum  
biochemistry histology  
evaluation with an  
image software 
6 weeks: PLLA-G-HA: ≈94%  
PLLA-HA: ≈64% Empty: 30%  
PLLA: 26% PLLA-G: 13%  
10 weeks: PLLA-G-HA: 98%  
PLLA-G: 80% PLLA-HA: 76%  
PLLA: 60% Empty: 34% 
No sign of  
inflammation 
Jiang et al. [36] rats 
5 mm calvarial defects,  
wound was closed with sutures. 
4 and  
8 weeks 
Micro-CT histology  
evaluation with an  
image software 
4 weeks: PLGA-HA-SIM: ≈4.2%  
PLGA-HA: <1% Empty: <1% 8  
weeks: PLGA-HA-SIM: ≈10%  
PLGA-HA: <4% Empty: <2% 
- 
Lee et al. [38] mice 
4 mm calvarial critical size  
defects, wound was closed  
with sutures. 
8 weeks 
Micro-CT SEM  
histology precise  
method of evaluation  
is not described 
PLLA + DA aligned fibers: 28.86 ± 6.5%  
PLLA+DA random fibers: 10.58 ± 0.9%  
PLLA aligned fibers: 5.25 ± 3.7%  
PLLA random fibers: 3.35 ± 1.8% 
No sign of  
inflammation 
Ko et al. [37] rats 
8 mm calvarial critical size  
defects, a polyvinyl  
membrane was laid over the  
defects and the wound was  
closed with sutures. 
8 and  
12 weeks 
Micro-CT nhistology  
precise method of  
evaluation is not described 
8 weeks: PLLA: minimal newly  
formed bone  
PLLA + DBP: greater extent of newly  
formed bone than PLLA alone  
12 weeks: PLLA: 70%  
PLLA + DBP: 90% 
PLLA: large numbers  
of inflammatory cells  
(12 weeks)  
PLLA + DBP: Minimal  
inflammatory reactions  
(12 weeks) 
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Table 2. Cont. 
Author Animal Model 
Defect Size (Diameter)  
and Wound Treatment 
Time of  
Evaluation 
Methods of Evaluation Area of Regenerated Bone 
Histological  
Results 
Schneider et al. [9] rabbits 
6 mm calvarial non-critical  
size, wound was closed  
with sutures. 
4 weeks 
Radiography Micro-CT  
histology evaluation with an  
image software 
PLGA/TCP: 34.9 ± 17%  
Bio Oss: 30.8 ± 14.3%  
Empty: 28.4 ± 14.9%  
PLGA: 25.1 ± 14.6% 
No sign of  
inflammation 
Schofer et al. [30] rats 
5 mm calvarial critical size  
defects, the wound was closed  
by suturing the overlaying tissue  
and skin. 
4, 8, and  
12 weeks 
CCT histology evaluation  
with an image software 
4 weeks: PLLA/BMP-2: 31% BS: 4%  
PLLA: 3% Empty: 1%  
8 weeks: PLLA/BMP-2: 48% BS: 6%  
LLA: 5% Empty: 3%  
12 weeks: PLLA/BMP-2: 48% BS: 26%  
PLLA: 2% Empty: 9% 
No sign of  
inflammation 
Shim et al. [31] rabbits 
8mm calvarial defects Wound  
was closed with sutures. 
2 and  
4 weeks 
histology - 
2 weeks: cells (mostly  
connective tissue and inflammatory  
cells) penetrated the  
three-dimensional scaffolds.  
4 weeks: new bone formation  
was observed 
Yanagida et al. [32] rats 
3 mm calvarial defects Wound  
was closed with sutures. 
4 weeks histology - 
PLLA: rarely new bone  
HAP-mixed/coated PLLA:  
new bone was more elongated 
BG: bioactive glass; BMP-2: bone morphogenetic protein 2; BS: bovine spongiosa; DA: dopamine; CCT: cranial computed tomography; DBP: demineralized bone powder; G: gelatin; HA: hydroxyapatite; MSCT: 
multislice spiral-computed tomography; SEM: scanning electron microscopy; SIM: simvastatin; TCP, tricalcium phosphate.  
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3.4.3. New Bone Formation at Different Time Points 
(1) PLGA 
Three studies examined PLGA scaffolds in the calvarial size models in rats [33,36] and rabbits [9]. 
One out of these three was performed in a critical size defect model [33].  
After four weeks, two studies [9,36] reported very different new bone formation. Jiang et al., found 
new bone formation accounting for 1% when PLGA-HA was used [36], whereas Schneider et al., 
found new bone formation for 25% (PLGA) and 34% (PLGA/TCP) [9]. The results of the control 
groups of these two investigations varied as well. The empty defects were filled with 1% [36] and 28% [9] 
newly formed bone, respectively. 
Examinations after eight weeks were performed in two studies in the rat calvarial model [33,36]. 
The control groups of these two investigations were approximately in the same range, accounting for 
2% [36] and 5% [33] newly formed bone. Pure PLGA scaffolds reported 35% new bone [33]. PLGA 
scaffolds combined with willmite gained up to 70% [33] new bone formation, whereas only 10% new 
bone could be formed with HA-SIM [36]. Figure 2 illustrates the area of regenerated new bone for the 
different studies. 
 
Figure 2. Overview of the different studies with the longest observation period and the 
following examined groups: empty, mere polymers (PLGA or PLLA), and composites (Co).  
If more than one composite, only the best result is illustrated. 
(2) PLLA 
Examinations investigating PLLA scaffolds were mostly made in the rat calvarial  
model [30,32,34,35,37]. One study was performed in mice [38] and another one in rabbits [31]. All of 
these studies evaluating new bone formation worked with a critical size defect model [30,34,35,37,38]. 
Unfortunately, two studies did not quantify the newly formed bone within these areas in their  
studies [31,32]. 
Only one study evaluated the bone formation after four weeks [30]. PLLA scaffolds produced 3% 
newly formed bone while the empty control group was filled with 1% newly formed bone. In 
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adjunction with BMP-2, PLLA scaffolds showed significantly more new bone formation, accounting 
for 31%. 
One study evaluated bone formation after six weeks [35]. The results showed that mere PLLA 
scaffolds produced 26% new bone. Blending with gelatin (G), PLLA scaffolds resulted in less bone 
(13%). Surprisingly, the empty control group showed 30% newly formed bone, thus more bone was 
formed than in the two groups mentioned before. Significantly more bone formation was found with 
HA (64%) and in combinations of PLLA with the two substances, namely G and HA (94%). 
Four studies [30,34,37,38] evaluated new bone formation after eight weeks and found results with 
pure PLLA scaffolds reaching from “minimal new formed bone” [37] to 13% newly formed bone [34]. 
The empty control group defects showed new bone formation between 3% [30] and 12% [34]. Various 
organic adjunctions combined with PLLA scaffolds augmented bone formation from “bone extent 
greater than PLLA alone” (PLLA and demineralized bone powder (DBP)) [37] via moderate better 
results with the following dimensions: PLLA and DBP [37] was slightly better than PLLA alone. The 
effect was moderate because the authors quantified bone augmentation just in words and not in 
percentage. PLLA-BG noted 20%, PLLA-HA 23%, PLLA-TCP 44%, and PLLA-HA-BG 63% greater 
bone amount than the control groups [34]. PLLA scaffolds with BMP-2 showed a new bone fraction 
area of 48% [30], which is in the range as the TCP adjunction. 
After 10 weeks, only one study [35] investigated bone formation with results ranging from 34% in 
the empty control group up to almost complete defect healing in the PLLA-G-HA (98%). The pure 
PLLA control showed a defect closure of 60%. 
Two studies reported 12-week results [30,37]. Although these two studies showed comparable 
results at the eight-week control, they showed very different results at the 12-week control. Ko et al., 
reported about 70% new bone formation with PLLA alone [37], whereas Schofer et al., reported only 
12% new bone formation when using pure PLLA [30]. Combination of PLLA with DBP showed 
almost complete defect closure (90%) [37], while PLLA/BMP-2 reported 48% [30] and a defect 
closure that did not change between the eighth and 12th weeks. 
3.4.4. Biocompatibility Based on the Descriptive Histological Evaluation 
(1) PLGA 
Adegani et al., and Schneider et al., did not find any sign of inflammation in the histological 
evaluation after four and eight weeks [9,33]. Jiang et al., did not assess biological reaction against the 
scaffold material [36]. Willmite [33] and TCP [9] showed no other healing performance concerning 
inflammation reactions in comparison to pure PLGA scaffolds or control groups. 
(2) PLLA 
Four studies found no sign of inflammation [30,34,35,38], whereas Ko et al., reported minimal 
inflammatory reactions in their histological evaluation within the time from eight to 12 weeks [37]. 
Shim et al., reported after two weeks about inflammatory and connective tissue cells penetrating PLLA 
scaffolds [31]. However, they did not report any inflammatory reactions after four weeks. These 
histological findings were in agreement with biochemical and hematological parameters, indicating no 
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infection due to scaffold implantation [35]. One study did not mention tissue reactions against PLLA 
scaffolds [32]. However, it remains unclear if any reaction against PLLA was visible or if they simply 
did not assess this aspect. Regarding the different adjunctions as TCP, HA, BG, DA, BMP-2,  
and G [30,34,35,38], no distinction was noted between the healing performance of the defects. 
4. Discussion 
The aim of this systematic review was to explore the efficiency of electrospun PLLA or PLGA 
scaffolds used as bone substitute materials in in vivo animal investigations. We focused on the amount 
of newly formed bone and the biological reactions that these bone substitute materials are provoking  
in vivo. 
The 10 studies included in this review differed in terms of material composition, animal model, 
defect size, time of evaluation, evaluation methods, applied statistical methods, and primary outcome. 
Due to the pronounced heterogeneity among these studies, precise conclusions could not be made. 
All the studies in this review chose calvarial defects for their experiments. This model is a  
non-load-bearing model (no mechanical stimuli) with rather poor blood supply (limited nutrition) and 
limited bone marrow (smaller number of progenitor cells) [43]. Consequently, the mere effect of an 
applied biomaterial can be investigated in a comprehensive manner. 
Concerning PLGA scaffolds, conflicting results were found after four weeks. Jiang et al., found 
remarkably less bone formation in their study within 5 mm defects than Schneider et al., did in 6 mm 
critical defects. Although PLGA ratios were 85:15 in both studies, the materials differed in fiber 
diameter and scaffold architecture. While Jiang et al., used scaffolds with smooth nanofibers [36], 
Schneider et al., used scaffolds in which even the fibers showed a porous structure [9]. TCP 
nanoparticles increased fiber roughness additionally. Scaffold architecture, such as porosity and pore 
size, plays a critical role in cell migration and bone formation into a scaffold [44,45]. A high porosity 
of nanofibers helps cell accommodation and facilitates the efficient exchange of nutrient substances 
between the scaffold and the environment [46–48]. It was examined that a 100 µm pore diameter is 
necessary for in vitro cell migration and a 300 µm pore diameter is necessary for tissue ingrowth and 
nutrient diffusion [46,49]. However, the effects of scaffold architecture on bone formation can differ 
depending on the studied materials [50,51]. Furthermore, there is also evidence that scaffold porosity 
can have no significant effect on bone formation [52]. So, it remains necessary to test each 
biodegradable scaffold to delineate its influence on bone regeneration. Another reason for the different 
results could be due to the different animal models for the bone regeneration process. Dog, sheep, goat, 
pig, and rabbit are the most commonly used models for bone regeneration, whereas dog, sheep, and pig 
are the models with the highest similarity to humans. Given the considerable dissimilarities with 
human bone, mice and rats are not counted as desirable models for bone studies [53], though in this 
review, most of the experiments were done using the rat model. 
Concerning PLLA scaffolds, four studies presented eight-week results [30,34,37,38]. The 
regenerated area of new bone was only slightly more for mere PLLA samples than for the empty 
control groups. Combinations of PLLA scaffolds with inorganic or organic components showed higher 
new bone values in comparison to empty control groups or pure PLLA scaffolds in all these studies. 
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Differences between the results are difficult to trace back, though the studies varied in scaffold 
architectures, defect sizes, and methods of evaluations. 
The results of the 12-week controls were conflicting regarding pure PLLA scaffolds [30,37]. To 
comment on this outcome is demanding because at the eight-week control, the results of the pure 
PLLA scaffolds of these two studies were in the same range. Differences in study design should have 
shown an effect in the eight-week control already. One interpretation is that the circumstances in the 
study continuance changed between eight and 12 weeks in some way in one of the studies. 
Focusing on the results from Schofer et al. [30], they showed an augmentation of newly formed 
bone between the four- and eight-week controls. At the 12-week control, the new-formed bone reached 
larger dimensions in the PLLA and the empty control group but not in the PLLA/BMP-2 group. An 
explanation of this observation could be that most carriers loaded with BMP-2 show an early burst of 
BMP-2 release with a reduction of retained BMP-2 release afterwards [54]. However, the BMP-2 
release of the incorporated BMP-2 in electrospun PLLA scaffolds seems to be prolonged and with 
good effects on bone formation within the first eight weeks. The augmentation of newly formed bone 
ceased afterwards, probably as a consequence of the beginning degradation of the PLLA scaffolds and 
the adjusted disposability of BMP-2. Similar findings were made by Fu et al. and Kim et al. [55,56], 
finding a benefit from incorporating BMP-2 into scaffolds in vitro and in vivo, namely in the first eight 
weeks after implantation. Unfortunately, Fu and Kim did not perform a 12-week control, so we do not 
know if the augmentation of bone volume reached its maximum after eight weeks, similar to the  
Schofer study. 
In contrast to Schofer et al., Ko et al., showed a significant augmentation in new bone formation 
from the eight-week to the 12-week control. They demonstrated cell ingrowth for up to 12 weeks after 
implantation. They observed greater calcium content at earlier time points with PLLA/DBP scaffolds 
in vitro compared to the pure PLLA scaffolds. As mineralization is one of the key processes for bone 
regeneration, the authors concluded an up-regulation of the mineralization process by incorporation of 
DBP into scaffolds and showed the in vivo performance of the combined PLLA/DBP scaffold as 
mentioned before. 
Generally, to improve the biological functionality of synthetic polymers, composite scaffolds have 
been developed using inorganic substances like HA, TCP, and BG. Bone is composed of  
nano-assembled collagen type 1 and inorganic HA crystals. Therefore, composite scaffolds with 
bioactive inorganic particles improve in vivo cell interaction. This effect was demonstrated in many in 
vitro and in vivo studies [57–59]. In this review, compositions of PLGA and PLLA scaffolds with 
inorganic substances support these findings, showing higher new bone formation than for mere polymeric 
scaffolds alone [9,33–36]. Additionally, the use of basic substances, such as HA, can hinder the 
degradation by neutralizing the buffer media and can even retain a higher percentage of the flexural 
strength [60]. As mentioned before, methods to evaluate newly formed bone varied in many aspects. 
Most of the studies used different radiographic methods to quantify newly formed bone areas [9,30,33–38]. 
Furthermore, two of them quantified bone augmentation by two independent radiologists [33,34], while the 
other authors [9,30,35–38] used software to analyze new bone volume. These factors should also be 
considered when comparing the results of the various studies and can partially explain the different results. 
Another approach to engineer an effective bone graft material is to integrate substances into the 
scaffold that are capable of triggering osteogenesis, such as growth factors [61]. In this review,  
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BMP-2 [30], DA [38], DBP [37], and SIM [36] were incorporated into PLLA/PLGA scaffolds. These 
factors can enhance bone growth compared to pure PLLA/PLGA scaffolds alone and compared to 
control groups in all studies included in this review, and this supports results from studies made with 
the named factors in vitro and in vivo [62–67]. 
PLLA is widely used in medical fields. A disadvantage of PLLA is low cell adhesion on its 
hydrophobic surface [68]. Another disadvantage is that degradation of PLLA leads to acidic products 
and these are supposed to produce inflammatory tissue reactions [20,69,70]. However, four out of six 
studies that assessed tissue reactions histologically did not find any signs of inflammation [30,34,35,38] for 
PLLA. The same held true for two PLGA studies [9,33]. Two studies reported inflammatory reactions 
in pure PLLA scaffolds [31,37]. One of these investigations also examined PLLA with DBP [37]. In 
this combination they assessed only minimal inflammatory reactions in comparison to pure PLLA 
scaffolds. This might be due to the starting biomineralization process, which could buffer a possible 
acidic degradation. 
5. Conclusions  
Scaffold composition and architecture determines its biological behavior and degradation 
characteristics. Therefore, each scaffold has to be tested on its properties in vitro and in vivo. 
Nevertheless, general statements can be made: 
PLLA and PLGA provide more new bone formation than empty control groups in vivo. 
PLLA/PLGA scaffold compositions with inorganic substances, such as HA, TCP, and BG and/or 
organic substances such as BMP-2, DA, DBP, and SIM enhance new bone formation additionally. 
Consequently, a combined scaffold should be favored. 
PLLA/PLGA composite scaffolds, especially when combined with basic substances like HA, seem 
to not induce inflammatory tissue reactions in vivo. 
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